Evidence map›Paper›PMID 41149714›Full record

ArticleJournal of functional biomaterials2025

Polyethyleneimine-Assisted Fabrication of Poly(Lactic-Co-Glycolic Acid) Nanoparticles Loaded with Tamibarotene (Am80) for Meflin Expression Upregulation.

Tomoya Inose, Tadashi Iida, Hiroki Kawashima, Atsushi Enomoto, Maki Nakamura, Ayako Oyane

Abstract read
In one paragraph

Article in Journal of functional biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomoya InoseResearch Institute of Core Technology for Materials Innovation, National Institute of Advanced Industrial Science and Technology (AIST), AIST Tsukuba Central 5, 1-1-1 Higashi, Tsukuba 305-8565, Japan.ORCID 0000-0001-6756-4503
Tadashi IidaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Shouwa-ku, Nagoya 466-8550, Japan.ORCID 0000-0001-5491-6012
Hiroki KawashimaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Shouwa-ku, Nagoya 466-8550, Japan.ORCID 0000-0002-3720-781X
Atsushi EnomotoDepartment of Pathology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Shouwa-ku, Nagoya 466-8550, Japan.ORCID 0000-0002-9206-6116
Maki NakamuraResearch Institute of Core Technology for Materials Innovation, National Institute of Advanced Industrial Science and Technology (AIST), AIST Tsukuba Central 5, 1-1-1 Higashi, Tsukuba 305-8565, Japan.ORCID 0000-0002-6759-3205
Ayako OyaneResearch Institute of Core Technology for Materials Innovation, National Institute of Advanced Industrial Science and Technology (AIST), AIST Tsukuba Central 5, 1-1-1 Higashi, Tsukuba 305-8565, Japan.ORCID 0000-0001-6037-5558

Funding

JSPS KAKENHI 24K11067
6 · The paper itself

Abstract

Tamibarotene (Am80) is a promising anti-tumor drug that induces the expression of Meflin (a glycosylphosphatidyl inositol-anchored protein) in cancer-associated fibroblasts, thereby improving the tumor microenvironment. However, Am80, which is approved only for oral administration owing to its poor water solubility, has the challenge of poor tumor penetration. In this study, we developed poly(lactic-co-glycolic acid) nanoparticles loaded with Am80 (Am80-PLGA nanoparticles) as a potential intravenous drug for targeted Am80 delivery to the tumor site. The Am80-PLGA nanoparticles were fabricated using the single-emulsion method in the presence of cationic polyethyleneimine (PEI). The loading efficiency of Am80 in the nanoparticles was controlled by tuning the PEI concentration in the preparation mixture. Nanoparticles with the highest Am80-loading efficiency were dispersible and showed a hydrodynamic diameter of approximately 190 nm in phosphate-buffered saline for up to 2 weeks. The Am80 release from the nanoparticles started in a day and lasted for weeks. The nanoparticles upregulated Meflin expression in human fibroblasts (fHDF/TERT166 cells). These results suggest the potential of Am80-PLGA nanoparticles as a new intravenous anti-tumor drug that can improve the tumor microenvironment, thereby enhancing the efficacy of chemotherapy and immunotherapy.

Indexed as

cancer-associated fibroblast (CAF)Meflinnanoparticlepolyethyleneimine (PEI)poly(lactic-co-glycolic acid) (PLGA)tamibarotene (Am80)

Identifiers

PMID41149714
PMCPMC12565359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.